A detailed history of American Portfolios Advisors transactions in Moleculin Biotech, Inc. stock. As of the latest transaction made, American Portfolios Advisors holds 334 shares of MBRX stock, worth $1,152. This represents 0.0% of its overall portfolio holdings.

Number of Shares
334
Holding current value
$1,152
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Mar 17, 2023

BUY
$1.15 - $1.9 $384 - $634
334 New
334 $354,000

Others Institutions Holding MBRX

# of Institutions
2
Shares Held
3.35K
Call Options Held
0
Put Options Held
0

About Moleculin Biotech, Inc.


  • Ticker MBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,606,700
  • Market Cap $98.7M
  • Description
  • Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs....
More about MBRX
Track This Portfolio

Track American Portfolios Advisors Portfolio

Follow American Portfolios Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

News

Stay updated on American Portfolios Advisors with notifications on news.